The aim of the present study was to identify factors predictive for long-term versus short-term survival of a real-world cohort of stage IV melanoma patients after onset of a modern first-line therapy with PD-1-based ICI or BRAF/MEK-directed TT. This evidence concerns the gene BRAF and melanoma.